Drug intelligence / Profile preview

OX-100

Development stage: Preclinical
Lead developer: OxaluRx
Modality: Small Molecules
Administration: Oral

Overview

OX-100 is a preclinical lead candidate developed by OxaluRx, a company created by RiverVest’s Archer Seed Fund. It is an oral small molecule therapy designed to treat genetic hyperoxaluria, a rare metabolic disease. The drug functions by inhibiting glycolate oxidase, thereby reducing the production of oxalate.

Targets

HAO1 (Glycolate Oxidase)

Beyond the preview

Go deeper on OX-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OX-100.

Explore the full profile